Anavex Life Scien…
USUSDAnavex Life Sciences Corp (US:AVXL) — Biotechnology: Biological Products (No Diagnostic Substances). Biržų, kuriose prekiaujama bendrovės akcijomis, skaičius: 2. Šiame puslapyje — kaina ir grafikas, dividendai, didžiausi akcininkai ir akcijų skaičiaus istorija.
Apie Įmonę
- Svetainė
- anavex.com
- Investuotojams
- anavex.com/investors/
- Sektorius
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Būstinė
- NEW YORK, United States
- Generalinis Direktorius
- Terrie Kellmeyer
- Darbuotojai
- 34
- Apyvartoje Esančios Akcijos
- 92.7 mln. 2026-08-28 duomenimis
- Laisvai Apyvartinės Akcijos
- 89.81 mln.
- Rinkos Kapitalizacija
- 138.12 mln. USD
- Insaideriai
- 1.71%
- Instituciniai Investuotojai
- 40.49%
- Šaka (SIC)
- Biological Products, (No Diagnostic Substances)
- FCF
- —
- Skola
- 345 USD
- Pelnas ir FCF – už 12 mėnesių iki 30.06.2026 (naujausia įmonės ataskaita).
Aprašymas
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Didžiausi Akcininkai
| Turėtojas | Dalis | Akcijos | Ataskaitos Data |
|---|---|---|---|
| Blackrock Inc. | 8.69% | 8.06 mln. | 2026-06-30 |
| Vanguard Capital Managem… | 4.37% | 4.05 mln. | 2026-06-30 |
| Two Sigma Investments, L… | 3.29% | 3.05 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.16% | 2.93 mln. | 2026-06-30 |
| Geode Capital Management… | 2.6% | 2.41 mln. | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.57% | 2.38 mln. | 2026-08-31 |
| Federated Hermes MDT Ser… | 2.21% | 2.05 mln. | 2026-07-31 |
| State Street Corporation | 2.07% | 1.92 mln. | 2026-06-30 |
| MISSLING CHRISTOPHER U (… | ≈1.63% | 1.51 mln. | 2025-09-11 |
| Federated Hermes, Inc. | 1.16% | 1.07 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.12% | 1.04 mln. | 2026-06-30 |
| Fidelity Salem Street Tr… | 1.08% | 1 mln. | 2026-07-31 |
| AQR Capital Management,… | 1.04% | 963 014 | 2026-06-30 |
| Vanguard Portfolio Manag… | 1.02% | 948 633 | 2026-06-30 |
| Summit Financial, LLC | 0.98% | 909 430 | 2026-06-30 |
| Goldman Sachs Group Inc | 0.96% | 890 634 | 2026-06-30 |
| iShares Trust-iShares Ru… | 0.79% | 729 592 | 2026-08-31 |
| iShares Trust-iShares Bi… | 0.72% | 667 442 | 2026-08-31 |
| VANGUARD SCOTTSDALE FUND… | 0.49% | 450 282 | 2026-05-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.47% | 440 209 | 2026-05-31 |
| iShares Trust-iShares Mi… | 0.34% | 312 610 | 2026-08-31 |
| THOMAS STEFFEN PHD (Dire… | ≈0.05% | 43 651 | 2025-06-05 |
Prisijunkite su Google